2. Hypoglycemia was not reported for any placebo patients. Thus, Glipizide was more effective when administered about 30 minutes before, rather than with, a test meal in diabetic patients. Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class.The Chemical Abstracts name of Glipizide is 1-cyclohexyl-3-[[p-[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea. This has been reported more frequently with the use of agents with prolonged half-lives. 7.2 Miconazole Monitor patients closely for hypoglycemia when glipizide extended-release tablets are coadministered with miconazole. The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. 0000001922 00000 n
It is insoluble in water and alcohols, but soluble in 0.1 N NaOH; it is freely soluble in dimethylformamide. The molecular formula is C 21 H 27 N 5 O 4 S; the molecular weight is 445.55; the structural formula is shown below: Potential Increased Risk of Cardiovascular Mortality with Sulfonylureas: Inform patient of risks, benefits and treatment alternatives ( 5.3 ) . UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone.
0000000016 00000 n
Total absorption and disposition of an oral dose was unaffected by food in normal volunteers, but absorption was delayed by about 40 minutes. Increased frequency of monitoring may be required when glipizide extended-release tablets is coadministered with these drugs. At such times, it may be necessary to discontinue Glipizide and administer insulin.The effectiveness of any oral hypoglycemic drug, including Glipizide, in lowering blood glucose to a desired level decreases in many patients over a period of time, which may be due to progression of the severity of the diabetes or to diminished responsiveness to the drug. 211 28
(5.1) • After initiation of pioglitazone tablets, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). Clinical Considerations Monitoring for adverse reactions Monitor breastfed infants for signs of hypoglycemia (e.g., jitters, cyanosis, apnea, hypothermia, excessive sleepiness, poor feeding, seizures).
The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of Glipizide. Hypersensitivity to sulfonamide derivatives. Common side effects include nausea, diarrhea, low blood sugar, …
These may be transient and may disappear despite continued use of Glipizide; if skin reactions persist, the drug should be discontinued.
The metabolic and excretory patterns are similar with the two routes of administration, indicating that first-pass metabolism is not significant. Macrovascular Outcomes: No clinical studies have established conclusive evidence of macrovascular risk reduction with glipizide extended-release tablets or any other anti-diabetic drug ( 5.4 ) . The study involved 823 patients who were randomly assigned to one of four treatment groups. Elderly patients are particularly susceptible to the hypoglycemic action of anti-diabetic agents. 7.1 Drugs Affecting Glucose Metabolism A number of medications affect glucose metabolism and may require glipizide extended-release tablets dose adjustment and close monitoring for hypoglycemia or worsening glycemic control. Click to view Minidiab/Minidiab OD detailed prescribing information Drug Interactions Increased hypoglycemic effects w/ antifungals, NSAIDs, salicylates, alcohol, β-blockers, ACE inhibitors, H 2 -receptor antagonists, sulfonamides, chloramphenicol, probenecid & coumarins. Measurement of glycosylated hemoglobin may be useful.Patients should be informed of the potential risks and advantages of Glipizide and of alternative modes of therapy. 0000002031 00000 n
xref
It is not indicated for use by itself in type 1 diabetes. Call your doctor for medical advice about side effects. Type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. In post-marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.Blood and urine glucose should be monitored periodically.